PD-1 drugs for Urothelial Carcinoma

4 tracked PD-1 drugs in the Urothelial Carcinoma race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Urothelial Carcinoma page.

3 approved / phase 41 Phase 2

Head-to-head evidence: Budigalimab vs Nivolumab · Budigalimab vs Pembrolizumab · Nivolumab vs Opdivo Qvantig · Nivolumab vs Pembrolizumab · Opdivo Qvantig vs Pembrolizumab

The roster

← all PD-1 drugs